Veru Stock Price, News & Analysis

Veru (NASDAQ: VERU) will report fiscal year 2025 financial results and provide a business update on Wednesday, December 17, 2025 at 8:00 a.m. ET. The company will host a conference call and live audio webcast accessible from the Home and Investors pages at www.verupharma.com. A replay of the webcast will be archived on the company website for approximately three months. A telephonic replay will be available from about 12:00 p.m. ET for one week by dialing the provided replay numbers with passcode 2225332.

Veru (NASDAQ: VERU) will present multiple times at The Society on Sarcopenia, Cachexia, and Wasting Disorders 18th International Conference and the SCWD Regulatory and Clinical Trials Update Workshop in Rome, Italy on December 11–13, 2025. Mitchell Steiner, Veru’s Chairman, President & CEO, is the company presenter.

Key sessions include: a workshop discussion on treatment approaches and regulatory issues for muscle wasting during obesity therapy (Dec 11, 10:15–11:15 CET and 11:15–11:55 CET), a presentation on weight loss drugs and cardiovascular health (Dec 12, 16:30–16:45 CET), and a roundtable on novel sarcopenia strategies while treating obesity including an update on Enobosarm (Dec 13, 10:00–10:15 CET). Locations: A. Roma Lifestyle Hotel, Hall A.

Veru (NASDAQ: VERU) will present two abstracts at ObesityWeek 2025 in Atlanta, November 4-7, 2025.

Poster: "Enobosarm Reduced Body Weight and Fat Regain and Preserved Lean Mass After Discontinuing Semaglutide" presented by Steven B. Heymsfield, M.D., on Tuesday, November 4, 2025, 7:30 pm–8:30 pm ET in Exhibit Hall A1. Oral: "Enobosarm in Combination With GLP-1RA is Selective for Fat Loss While Preserving Lean and Function" presented by Mitchell Steiner, M.D., on Friday, November 7, 2025, 8:00 am–8:15 am ET in GWCC Building A: A411-A412.

Additional meeting details are available at https://obesityweek.org/.

Veru (NASDAQ: VERU)Oct 30, 2025 consisting of 1,400,000 common shares, pre-funded warrants for up to 7,000,000 shares, and accompanying Series A and Series B warrants to purchase up to 8,400,000 shares each.

The combined public offering price per share with warrants is $3.00 (pre-funded combined price $2.999). Gross proceeds are expected to be approximately $25.2 million at closing (on or about Oct 31, 2025); cash exercise of all warrants would yield an additional $50.4 million. Net proceeds are planned to fund development of enobosarm, primarily the Phase 2b PLATEAU clinical study, and for working capital and general corporate purposes.

Veru (NASDAQ: VERU) announced on October 29, 2025 that it has commenced an underwritten public offering of shares of common stock (or pre-funded warrants) together with accompanying Series A and Series B warrants. The offering is subject to market and other conditions and may not be completed.

Use of proceeds is stated as funding development of enobosarm with a primary focus on the Phase 2b PLATEAU clinical study, plus working capital, existing vendor obligations, and potential development partner activities. Canaccord Genuity and Oppenheimer are joint book-running managers. The securities will be offered under a shelf registration statement on Form S-3 declared effective April 14, 2023, with a preliminary prospectus supplement to be filed with the SEC.

Veru (NASDAQ: VERU) announced a successful FDA meeting regarding enobosarm, their muscle preservation drug candidate for obesity treatment. The FDA provided key regulatory clarity, accepting incremental weight loss as a primary endpoint when enobosarm is combined with GLP-1 RA treatments. The agency confirmed 3mg as an acceptable dosage and encouraged expanding the program to younger obesity patients.

Based on their positive Phase 2 QUALITY study results, Veru plans to initiate a Phase 2b PLATEAU clinical study in Q1 2026. The study will evaluate enobosarm 3mg in approximately 180 patients, both older (≥65) and younger (<65), who are starting tirzepatide treatment. The trial aims to demonstrate enobosarm's ability to preserve muscle mass while promoting additional fat loss, particularly in patients reaching the GLP-1 RA weight loss plateau.

Veru Inc. (NASDAQ: VERU) reported positive results from its Phase 2b QUALITY study evaluating enobosarm in combination with semaglutide for weight loss management. The study showed that enobosarm 3mg + semaglutide achieved 100% preservation of lean mass compared to placebo + semaglutide at 16 weeks (p<0.001). The combination resulted in 100% fat mass loss versus 66% for placebo + semaglutide.

In the Maintenance Extension study, enobosarm 3mg reduced body weight regain by 46% after semaglutide discontinuation. The company also announced a novel modified release oral enobosarm formulation with patent protection through 2046. For Q3 2025, Veru reported reduced operating losses of $7.5 million compared to $10.5 million year-over-year, with cash reserves of $15.0 million as of June 30, 2025.

Veru Inc. (NASDAQ: VERU) has achieved a significant milestone in drug development by selecting a novel modified-release oral formulation of enobosarm using Laxxon Medical's proprietary SPID® (Screen Printing Innovation Drug)-Technology.

The new tablet formulation demonstrated successful target release profiles, including reduced maximum plasma concentration (Cmax), delayed time to maximum plasma concentration (Tmax), a distinct secondary peak plasma concentration, and similar absorption extent compared to immediate release capsules.

This development marks a crucial step as Veru advances towards Phase 3 clinical trials and potential commercialization of enobosarm, pending regulatory approval.

Veru Inc. (NASDAQ: VERU) has successfully developed a novel modified release oral formulation for enobosarm, a selective androgen receptor modulator targeted for chronic weight loss management. The company completed a single dose, open label pilot study that confirmed the desired pharmacokinetic profile of the new 3mg formulation.

The study demonstrated key improvements including reduced maximum plasma concentration, delayed time to maximum plasma concentration, and a distinct secondary peak plasma concentration, while maintaining similar absorption compared to immediate release capsules. The formulation, developed in partnership with Laxxon Medical using SPID®-Technology, is protected by patents through 2037, with new patent applications potentially extending protection until 2046.